Plain-English translation of NCT07574047 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether the time of day you receive immunotherapy (ICI) affects how well it works against advanced melanoma. Researchers have noticed that the immune system may respond better to treatment at certain times of day, and early data suggests that receiving the medication in the morning rather than late afternoon might improve survival—especially for women. This trial will randomly assign participants to receive their standard immunotherapy either in the early morning (8am–12pm) or late afternoon (3pm–6pm) to find out which timing works best.
While immunotherapy has transformed melanoma treatment, not all patients respond equally, and survival outcomes vary by sex and age. Recent data suggest that the timing of treatment may matter because the immune system has natural daily rhythms that affect how well it responds. This trial exists to determine whether scheduling treatment at the optimal time of day can improve survival without adding new drugs or risks.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive your standard immunotherapy infusions either in the early morning or late afternoon window. You will continue receiving the same cancer treatment your doctor would normally prescribe, but on a specific schedule. Your doctor will monitor you with regular visits and scans to track how well the treatment is working and watch for any side effects. The trial will follow you over time to compare how patients who received morning infusions versus afternoon infusions respond to treatment.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
Switzerland